Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218085

SCHEMBL23218085

SCHEMBL23218085

CCOC(=O)Cc1ccc(C)cc1OCc1nn(C)c2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 4/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ PAK4 O96013 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ MET P08581 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ PIM1 P11309 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ PRKACA P17612 1/20 0.39
▸ GRK5 P34947 1/20 0.39
▸ MAP2K2 P36507 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ GSK3A P49840 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218159 0.90 ELANE (0.42) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL29591729 0.89 CFD (0.47) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL23218172 0.89 CFD (0.47) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL23218627 0.88 JAK2 (0.39) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL29121852 0.85 PTGDR2 (0.37) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL29853030 0.83 JAK2 (0.39) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL23218575 0.83 JAK2 (0.39) ELANESMN1; SMN2JAK2PAK4NTRK1
SCHEMBL29122297 0.82 SMN1; SMN2 (0.35) SMN1; SMN2CSF1RGSK3AGSK3BCFD
SCHEMBL23219047 0.82 CFD (0.54) SMN1; SMN2CFDDPP4
SCHEMBL29852878 0.82 CFD (0.54) SMN1; SMN2CFDDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 — — CN disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 ELANE 110/4885SMN1; SMN2 4845/4885JAK2 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.